Clinical Trial Update: Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) [Phase 2, Phase 3]

View source ↗

Summary

Open-label Phase 2/3 trial assessing the efficacy and safety of pozelimab in CD55-deficient protein-losing enteropathy (CHAPLE disease) has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd55-deficient Protein-losing Enteropathy

Drugs mentioned

• Pozelimab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: CD55-deficient Protein-losing Enteropathy, CHAPLE | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-10-30